The use of antibiotics and corticosteroids had proven to be a cost-effective strategy in treating community-acquired pneumonia. Together, they resulted in savings of $142,795 per death averted. In severe cases of community-acquired pneumonia, the combination of antibiotics and corticosteroids yielded savings of $70,587 and had an 82.6% chance of being cost-effective. The cost effectiveness of ceftolozane/tazobactam versus meropenem was also analyzed and resulted in significant savings in early treatment..
Bacterial pneumonia cost-effectiveness of therapy
Pneumonia cost-effectiveness of therapy
Hospital-acquired pneumonia cost-effectiveness of therapy
Acute respiratory distress syndrome cost-effectiveness of therapy
Pneumoconiosis cost-effectiveness of therapy
Pulmonary embolism cost-effectiveness of therapy
Tuberculosis cost-effectiveness of therapy
Multi-drug-resistant tuberculosis cost-effectiveness of therapy